MF-438
Based on 7 publication(s) in Google Scholar
MF-438 is a potent and orally bioavailable stearoyl-CoA desaturase 1 (SCD1) inhibitor with an IC50 of 2.3 nM for rSCD1.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.83%
- CAS No.: 921605-87-0
- Formule: C19H18F3N5OS
- Masse moléculaire:421.44
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) MF-438
More- Imeta. 2026 Feb 19.
- Gastroenterology. 2024 May;166(5):772-786.e14. [Abstract]
- Cancer Discov. 2023 Jul 7;13(7):1720-1747. [Abstract]
- Nat Cell Biol. 2024 Sep;26(9):1470-1481. [Abstract]
- Nat Commun. 2026 May 11;17(1):4190. [Abstract]
- EBioMedicine. 2022 Mar:77:103872. [Abstract]
- J Ovarian Res. 2025 Aug 11;18(1):180. [Abstract]
Activité biologique
EC50: 2.3 nM (rSCD1)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Hepatocyte | IC50 |
157 nM
Compound: 1, MF-438
|
Inhibition of SCD-1 activity in Sprague-Dawley rat Hepatocytes expressing organic anion transporting polypeptides assessed as reduction in [I-14C] stearoyl CoA desaturation by scintillation counting
Inhibition of SCD-1 activity in Sprague-Dawley rat Hepatocytes expressing organic anion transporting polypeptides assessed as reduction in [I-14C] stearoyl CoA desaturation by scintillation counting
|
[PMID: 21661758] |
| HepG2 | IC50 |
>100000 μM
Compound: 1, MF-438
|
Inhibition of human delta6 desaturase activity expressed in human HEpG2 cells
Inhibition of human delta6 desaturase activity expressed in human HEpG2 cells
|
[PMID: 21661758] |
| HepG2 | IC50 |
>100000 μM
Compound: 1, MF-438
|
Inhibition of rat delta-5 desaturase activity expressed in human HEpG2 cells
Inhibition of rat delta-5 desaturase activity expressed in human HEpG2 cells
|
[PMID: 21661758] |
| HepG2 | IC50 |
>100000 μM
Compound: 1, MF-438
|
Inhibition of rat delta-6 desaturase activity expressed in human HEpG2 cells
Inhibition of rat delta-6 desaturase activity expressed in human HEpG2 cells
|
[PMID: 21661758] |
| HepG2 | IC50 |
21 nM
Compound: 1, MF-438
|
Inhibition of SCD-1 activity in organic anion transporting polypeptides-deficient human HepG2 cells assessed as reduction in [I-14C] stearoyl CoA desaturation by scintillation counting
Inhibition of SCD-1 activity in organic anion transporting polypeptides-deficient human HepG2 cells assessed as reduction in [I-14C] stearoyl CoA desaturation by scintillation counting
|
[PMID: 21661758] |
| HepG2 | IC50 |
>100000 μM
Compound: 1, MF-438
|
Inhibition of human delta-5 desaturase activity expressed in human HEpG2 cells
Inhibition of human delta-5 desaturase activity expressed in human HEpG2 cells
|
[PMID: 21661758] |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 921605-87-0
-
Appearance Solid
-
Masse moléculaire 421.44
-
Formule C19H18F3N5OS
-
Color Light yellow to orange
-
SMILES
FC(C1=CC=CC=C1OC2CCN(C3=NN=C(C4=NN=C(C)S4)C=C3)CC2)(F)F
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
-
Gastroenterology
2024 May;166(5):772-786.e14. PMID: 38272100 -
Cancer Discov
C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia. [Abstract]2023 Jul 7;13(7):1720-1747. PMID: 37012202 -
Nat Cell Biol
Zeb1 mediates EMT/plasticity-associated ferroptosis sensitivity in cancer cells by regulating lipogenic enzyme expression and phospholipid composition. [Abstract]2024 Sep;26(9):1470-1481. PMID: 39009641 -
Nat Commun
Ascites protects against ferroptosis and enables the peritoneal growth of ovarian cancer. [Abstract]2026 May 11;17(1):4190. PMID: 42115216 -
EBioMedicine
2022 Mar:77:103872. PMID: 35158113 -
J Ovarian Res
2025 Aug 11;18(1):180. PMID: 40790593
Solvant et solubilité
DMF : 50 mg/mL (118.64 mM; Need ultrasonic)
DMSO : 25 mg/mL (59.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMF 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.93 mM); Clear solution
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.83 mg/mL (1.97 mM); Clear solution
This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.83 mg/mL (1.97 mM); Clear solution
This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / DMF | 1 mM | 2.3728 mL | 11.8641 mL | 23.7282 mL | 59.3204 mL |
| 5 mM | 0.4746 mL | 2.3728 mL | 4.7456 mL | 11.8641 mL | |
| 10 mM | 0.2373 mL | 1.1864 mL | 2.3728 mL | 5.9320 mL | |
| 15 mM | 0.1582 mL | 0.7909 mL | 1.5819 mL | 3.9547 mL | |
| 20 mM | 0.1186 mL | 0.5932 mL | 1.1864 mL | 2.9660 mL | |
| 25 mM | 0.0949 mL | 0.4746 mL | 0.9491 mL | 2.3728 mL | |
| 30 mM | 0.0791 mL | 0.3955 mL | 0.7909 mL | 1.9773 mL | |
| 40 mM | 0.0593 mL | 0.2966 mL | 0.5932 mL | 1.4830 mL | |
| 50 mM | 0.0475 mL | 0.2373 mL | 0.4746 mL | 1.1864 mL | |
| DMF | 60 mM | 0.0395 mL | 0.1977 mL | 0.3955 mL | 0.9887 mL |
| 80 mM | 0.0297 mL | 0.1483 mL | 0.2966 mL | 0.7415 mL | |
| 100 mM | 0.0237 mL | 0.1186 mL | 0.2373 mL | 0.5932 mL |
MF-438 Related Classifications
HY-15822 Related Classifications
Powered by Bioz